Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Tennessee

Peptide legality · Tennessee · updated 2026-09-21

Are peptides legal in Tennessee?

Gray area

Peptides fall in a gray zone in Tennessee, where legal prescription and compounding pathways coexist with active consumer-protection scrutiny of GLP-1 marketing and no clear status for many research peptides.

Legal status overview

Peptides occupy a gray zone in Tennessee. The state largely follows the federal compounding floor while it studies in-state compounding licensing requirements, and the Tennessee Attorney General has issued a consumer warning about GLP-1 weight-loss marketing, signaling active enforcement attention. FDA-approved peptide drugs are legal by prescription, and 503A patient-specific compounding is permitted when it satisfies federal criteria, but substances such as BPC-157 and TB-500 lack any affirmative compounding clearance and gray-market sales for human use remain unlawful. As elsewhere, the deciding factors are the prescriber relationship and the sourcing, not the label peptide.

Key points

  • Tennessee follows the federal FD&C Act 503A and 503B compounding baseline and has not codified a peptide standard stricter than federal law, though it is reported to be weighing in-state compounding licensing requirements. [4]
  • The Tennessee Attorney General's Consumer Protection Division issued a public warning about GLP-1 weight-loss product marketing, showing state-level enforcement interest beyond the pharmacy board. [5]
  • On April 15, 2026 the FDA removed BPC-157 and other peptides from 503A Category 2 without adding them to Category 1, so they remain outside the set of substances affirmatively eligible for compounding. [3]
  • The FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 in July 2026 to recommend adding BPC-157 to Category 1, but that recommendation is not final rulemaking and does not yet change the substance's status. [7]
  • After the FDA declared the GLP-1 shortage resolved in early 2025, compounded semaglutide and tirzepatide may be prepared only for a documented patient-specific clinical reason under a valid prescription. [2]
  • A compounded peptide is not FDA-approved; not a generic; not evaluated by the FDA, and is available only through a licensed prescriber paired with a licensed compounding pharmacy. [1]
  • Human growth hormone (somatropin) is separately restricted: distribution for any purpose other than an FDA-recognized indication under a valid prescription is a federal crime under 21 U.S.C. 333(e). [6]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved and holds no USP monograph. Removed from Category 2 in April 2026 but not in Category 1. A July 2026 advisory-committee vote recommended Category 1 inclusion, but that is not final.
GLP-1 class (Wegovy® (semaglutide), Zepbound® (tirzepatide))
Legal
FDA-approved brand products are legal by prescription. Compounded versions are not FDA-approved; not a generic; not evaluated by the FDA and are limited to documented patient-specific need, an area the Tennessee Attorney General is watching.
TB-500 (thymosin beta-4 fragment)
Gray area
Not FDA-approved. Removed from Category 2 in April 2026 without Category 1 placement, so no lawful compounding pathway is established. Prohibited in sport by WADA.
Growth hormone / somatropin
Restricted
FDA-approved for defined deficiency and wasting indications by prescription only. Distribution for anti-aging, bodybuilding, or athletic use is barred under 21 U.S.C. 333(e) even with a prescription.

Frequently asked questions

Are peptides legal in Tennessee?

It depends on the specific peptide and how it is obtained. FDA-approved peptide medicines are legal by prescription, and patient-specific compounding is allowed under federal rules, but many research peptides have no clear legal compounding status and are not sold lawfully for human use. This is information, not legal or medical advice.

Is compounded semaglutide legal in Tennessee?

Compounded semaglutide is not FDA-approved; not a generic; not evaluated by the FDA. Since the shortage ended it may be compounded only for a documented patient-specific clinical reason. The Tennessee Attorney General has also warned consumers about GLP-1 weight-loss marketing.

Can a Tennessee pharmacy compound BPC-157?

BPC-157 is not FDA-approved and, after its April 2026 removal from Category 2, was not added to Category 1. A July 2026 advisory vote recommended adding it, but until final rulemaking its compounding status remains unsettled.

Does Tennessee have a peptide-specific law?

Tennessee currently follows the federal compounding framework and has not enacted a stricter peptide statute, though it is reported to be considering in-state compounding licensing requirements. Oversight comes from the Tennessee Board of Pharmacy.

Is human growth hormone legal in Tennessee?

Somatropin is FDA-approved for specific indications by prescription. Distributing it for anti-aging, bodybuilding, or athletic performance is a federal crime under 21 U.S.C. 333(e), even with a prescription.

General information based on the sourced research above, not legal advice. For a specific situation in Tennessee, consult a licensed attorney familiar with pharmaceutical law.